The glucagon-like peptide-1 (GLP-1) receptor agonist liraglutide is the first in its class to show benefits in young children with obesity, according to results from the phase 3a SCALE-KIDS trial presented at the European Association for the Study of Diabetes (EASD) 2024 Annual Meeting and simultaneously published in the New England Journal of Medicine…
